PUBBLICAZIONI

Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 Influenza pandemic.

Magalhaes I, Eriksson M, Linde C, Muhammad R, Rane L, Ambati A, Axelsson-Robertson R, Khalaj B, Alvarez-Corrales N, Lapini G, Montomoli E, Linde A, Pedersen NL, Maeurer M.

BMC Infect Dis. 2014 Jun 11;14(1):319. [Epub ahead of print]

Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals

Eleonora Molesti, Francesca Ferrara, Giulia Lapini, Emanuele Montomoli, Nigel James Temperton

BioMed Research International (Impact Factor: 2.88). 05/2014;

Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge.

Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, Veldhuis Kroeze EJ, Hinchcliffe M, Smith A, Montomoli E, Piccirella S, Osterhaus AD, Knight A, Oxford JS, Lapini G, Cox R, Lambkin-Williams R.

PLoS One. 2014 May 21;9(5):e93761

Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.

Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR.

Biotechnol J. 2014 Mar;9(3):405-14.

A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen Å, Guzmán CA,Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, Cox RJ.

Influenza Other Respir Viruses. 2013 Nov;7(6):1181-93.

Swine influenza and vaccines: an alternative approach for decision making about pandemic prevention.

Basili M, Ferrini S, Montomoli E.

Eur J Public Health. 2013 Aug;23(4):669-73. doi: 10.1093/eurpub/ckt004. Epub 2013 Mar 26.

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: Results of a randomized, controlled comparison.

Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, Research Network CI.

Hum Vaccin Immunother. 2013 Jul 9;9(11).

Understanding the dynamics of seasonal influenza in Italy: incidence, transmissibility and population susceptibility in a 9-year period.

Lunelli A, Rizzo C, Puzelli S, Bella A, Montomoli E, Rota MC, Donatelli I, Pugliese A.

Influenza Other Respir Viruses. 2013 May;7(3):286-95.

Dataset: TBE ISW Conference report Vaccine 2011

Kunze U, Andreassen A, Aspöck H, Atkinson B, Avdicova M, Balogh Z,Baumhackl U, Chatterjee S, Chitimia L, Chmelik V, Christiansen C, DĭAncona F, Deryabin P, Dobler G, Donoso-Mantke O, Ergunay K, Freund C, Gasche N, Grubeck-Loewenstein B, Haditsch M, Haglund M, Heinz F, Hewson R,Holzmann H, Hufert F, Jaago K, Jääskeläinen A, Jilkovà E, Kahl O, Kapeller P,Karelis G, Kharit S, Kimmig P, Kollaritsch H, Komorek M, Konior R, Krech T,Kulcsar A, Kunz C, Kunze M, Liang G, Lindqvist L, Mackenstedt U, Marth E,Meyding-Lamadè U, Mickiene A, Montomoli E, Nieminen T, Novak H, Oehme R, Pfeffer M, Platonov A, Poponnikova T, Prelog M, Prymula R, Randolph S,Stanek G, Stefanoff P, Steffen R, Strle F, Strondl A, Süss J, Takashima I,Vaheri A, Vainio K, Vorobyeva M, Wagner L, Wanke K, Wiedermann-Schmidt U, Zajkowska J, Zampachova A, Zilmer K, Zöldi V

Article: Tick-borne encephalitis (TBE): An underestimated risk…still

Ursula Kunze, Aspöck H, Avdičová M, Caumes E, Chitima L, Chlibek R,Christiansen CB, Cleton N, Czajka H, Dautel H, Dobler G, Engmann ML,Košnik IG, Haditsch M, Haglund M, Hansmann Y, Heinz FX, Hjertqvist M, Hoel T, Hrabcik H, Jaago K, Jääskeläinen A, Jelenik Z, Jilkovà E, Kahl O, Kimmig P,Kollaritsch H, Krech T, Kunze M, Lidefelt KJ, Mackenstedt U, Madar R, Marth E, Mickiene A, Montomoli E, Oehme R, Péter O, Petko B, Pfeffer M, Póta G,Prymula R, Ruscio M, Stanek G, Steffen R, Sundin M, Süss J, Taba P, Tonteri E, Turk K, Vaheri A, Vakkila J, Wieten R, Würzner R, Zajkowska J, Zilmer K,Zygutiene M

Ticks and Tick-borne Diseases (Impact Factor: 2.35). 06/2012; 3(3):197-201.

 

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.

Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G.

Expert Rev Vaccines. 2012 May;11(5):587-94.

 

The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.

Jul-Larsen Å, Madhun AS, Brokstad KA, Montomoli E, Yusibov V, Cox RJ.

Hum Vaccin Immunother. 2012 May;8(5):653-61.

 

 

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.

Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G.

Vaccine. 2012 Jun 8;30(27):4086-94

 

The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.

Svindland SC, Jul-Larsen Å, Pathirana R, Andersen S, Madhun A, Montomoli E, Jabbal-Gill I, Cox RJ.

Influenza Other Respir Viruses. 2012 Mar;6(2):90-100.

 

Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study.

Carraro G, Naso A, Montomoli E, Gasparini R, Camerini R, Panatto D, Tineo MC, De Giorgi L, Piccirella S, Khadang B, Ceracchi M, De Rosa A.

Vaccine. 2012 Feb 1;30(6):1170-80.

 

Current adjuvants and new perspectives in vaccine formulation.

Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A.

Expert Rev Vaccines. 2011 Jul;10(7):1053-61.

 

Collaborative study on influenza vaccine clinical trial serology – part 2: reproducibility study.

Wood JM, Montomoli E, Newman RW, Daas A, Buchheit KH, Terao E.

Pharmeur Bio Sci Notes. 2011 Jun;2011(1):36-54.

 

Tick-borne encephalitis: the impact of epidemiology, changing lifestyle, and environmental factors. Conference report of the 12th Annual Meeting of the International Scientific Working Group on Tick-Borne Encephalitis (ISW-TBE).

Kunze U; ISW TBE.

Andreassen A, Aspöck H, Atkinson B, Avdicova M, Balogh Z, Baumhackl U, Chatterjee S, Chitimia L, Chmelik V, Christiansen C, DĭAncona F, Deryabin P, Dobler G, Donoso-Mantke O, Ergunay K, Freund C, Gasche N, Grubeck-Loewenstein B, Haditsch M, Haglund M, Heinz F, Hewson R, Holzmann H, Hufert F, Jaago K, Jääskeläinen A, Jilkovà E, Kahl O, Kapeller P, Karelis G,Kharit S, Kimmig P, Kollaritsch H, Komorek M, Konior R, Krech T, Kulcsar A, Kunz C, Kunze M, Liang G, Lindqvist L,Mackenstedt U, Marth E, Meyding-Lamadè U, Mickiene A, Montomoli E, Nieminen T, Novak H, Oehme R, Pfeffer M, Platonov A, Poponnikova T, Prelog M, Prymula R, Randolph S, Stanek G, Stefanoff P, Steffen R, Strle F, Strondl A, Süss J, Takashima I, Vaheri A, Vainio K, Vorobyeva M, Wagner L, Wanke K, Wiedermann-Schmidt U, Zajkowska J, Zampachova A, Zilmer K, Zöldi V.

Vaccine. 2011 Feb 4;29(7):1355-6. doi: 10.1016/j.vaccine.2010.12.048. Epub 2011 Jan 1.

 

Chapter: Correlates of Protection Against Influenza

Emanuele Montomoli, Barbara Capecchi, Katja Hoschler

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.

Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP.

PLoS One. 2010 Dec 22;5(12):e15559.

 

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.

Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A.

Clin Vaccine Immunol. 2010 Nov;17(11):1817-9.

 

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R.

Pediatrics. 2010 Oct;126(4):e762-70.

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, Icardi G.

Vaccine. 2010 Jun 7;28(25):4123-9.

Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period.

Rizzo C, Rota MC, Bella A, Alfonsi V, Declich S, Caporali MG, Ranghiasci A, Lapini G, Piccirella S, Salmaso S, Montomoli E.

Vaccine. 2010 Apr 30;28(20):3558-62.

 

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.

Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B.

Vaccine. 2009 Oct 9;27(43):5998-6003.

 

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pöllabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P.

J Infect Dis. 2009 Oct 1;200(7):1113-8.

Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice.

Dormitzer PR, Rappuoli R, Casini D, O’Hagan D, Runham C, Montomoli E, Baudner B, Donnelly Iii JJ, Lapini G, Wack A.

Version 2. PLoS Curr. 2009 Aug 31 [revised 2009 Sep 1];1:RRN1025.

 

 Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7.

 

How much ozone bactericidal activity is compromised by plasma components?

Burgassi S, Zanardi I, Travagli V, Montomoli E, Bocci V.

J Appl Microbiol. 2009 May;106(5):1715-21.

Hepatitis A seroprevalence in Tuscany, Italy.

Gentile C, Alberini I, Manini I, Rossi S, Montomoli E, Pozzi T, Rizzo C, Alfonsi V.

Euro Surveill. 2009 Mar 12;14(10).

 

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.

Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A.

PLoS One. 2009;4(2):e4384. doi: 10.1371/journal.pone.0004384. Epub 2009 Feb 6. Erratum in: PLoS ONE. 2009;4(3).

 

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.

Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A.

Vaccine. 2009 Jan 29;27(5):786-91.

Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania.

Pippi F, Bracciale L, Stolzuoli L, Giaccherini R, Montomoli E, Gentile C, Filetti S, De Luca A, Cellesi C.

HIV Med. 2008 Aug;9(7):519-25.

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team.

N Engl J Med. 2008 Jun 12;358(24):2573-84.

 

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.

Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P.

Vaccine. 2008 Mar 17;26(12):1525-9.

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O’Hagan DT.

Vaccine. 2008 Jan 24;26(4):552-61.

 

Article: Priming for Pandemic Influenza: Antigen-sparing MF59™-adjuvanted A/H5N1 Vaccine Induces Immunological Memory and Shows Cross-Reactive Potential in Adults Including the Elderly

V. F. H. Brauer, F. Laghi-Pasini, P. L. Capecchi, C. Gentile, P. di Giovanni, T. Staniscia, E. Montomoli, A. Hilbert, S. Tilman, P. Durando, L. Sticchi, R. Gasparini

International Journal of Infectious Diseases – INT J INFECT DIS. 01/2008; 12.

 

Susceptibility to varicella in childbearing age women, Central Italy: is there a need for vaccinating this population group?

Alfonsi V, Montomoli E, Manini I, Alberini I, Gentile C, Rota MC, Ciofi degli Atti ML.

Vaccine. 2007 Aug 10;25(32):6086-8.

 

Pre-emptive vaccination against pandemic influenza virus.

Montomoli E, Manini I.

Vaccine. 2007 Mar 1;25(11):1921-2.

 

Article: P1218 Hepatitis A infection in central Tuscany in children and youths

C. Gentile, I. Alberini, I. Manini, E. Montomoli, S. Rossi, T. Pozzi

International Journal of Antimicrobial Agents – INT J ANTIMICROBIAL AGENTS. 01/2007; 29.

Influenza-related mortality in the Italian elderly: no decline associated with increasing vaccination coverage.

Rizzo C, Viboud C, Montomoli E, Simonsen L, Miller MA.

Vaccine. 2006 Oct 30;24(42-43):6468-75.

 

Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy.

Pütz MM, Alberini I, Midgley CM, Manini I, Montomoli E, Smith GL.

J Gen Virol. 2005 Nov;86(Pt 11):2955-60.

A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines.

Oxford JS, Manuguerra C, Kistner O, Linde A, Kunze M, Lange W, Schweiger B, Spala G, Rebelo de Andrade H, Pérez Breña PR, Beytout J, Brydak L, Caraffa de Stefano D, Hungnes O, Kyncl J,Montomoli E, Gil de Miguel A, Vranckx R, Osterhaus A.

Vaccine. 2005 Nov 16;23(46-47):5440-9.

Article: A method for detection of neuraminidase antibody in serum

E Montomoli, K Cavallaro, V Alfonsi, I Manini, E Battisti, A Provvedi,C Rizzo, R Gasparini

International Congress Series 01/2004; 1263:524-527.

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects.

Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A.

Eur J Epidemiol. 2001;17(2):135-40.

Morpho-structural variations of bacterial spores after treatment in steam vacuum assisted autoclave.

Fonzi M, Montomoli E, Gasparini R, Devanna D, Fonzi L.

Bull Group Int Rech Sci Stomatol Odontol. 1999 Oct-Dec;41(4):124-30.

Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy.

Bonanni P, Colombai R, Gasparini R, Lo Nostro A, Tiscione E, Tomei A, Montomoli E, Comodo N.

Pediatr Infect Dis J. 1999 Aug;18(8):677-82

Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy.

Cellesi C, Sansoni A, Casini S, Migliorini L, Zacchini F, Gasparini R, Montomoli E, Bonacci A, Bravi A.

Atherosclerosis. 1999 Jul;145(1):81-5.

Article: Patient information, attitude and behaviour concerning influenza vaccination at the polyclinic of Siena

R Gasparini, A Ciliberti, M Gulino, E Montomoli, P Durando, L Sticchi, P Crovari

Article: Short Communication Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy

Mike M. Putz, Isabella Alberini, Claire M. Midgley, Ilaria Manini, Emanuele Montomoli, Geoffrey L. Smith

Article: Tetanus Epidemiology in Europe and in Italy: a review

R. GASPARINI, E. MONTOMOLI, S. MASSAFRA, C. GIOSCIA, E. FRAGAPANE, C. BONNAL, P. BONANNI